CytRx initiated a Phase 2 clinical trial evaluating the preliminary efficacy and safety of INNO-206 in patients with advanced pancreatic ductual adenocarcinomas who have progressed after receiving two prior therapies. PDA is a malignant tumor arising from the duct cells within a gland in the pancreas, and represents about 80% of all pancreatic cancers. CytRx holds the worldwide rights to INNO-206, which has been granted orphan drug designation by the FDA for the treatment of patients with pancreatic cancer.
Happy demi-anniversary, stock market rally. Will the honeymoon ever end?